Get all premium features to the best stock analysis tool

Finranks

Company

About us

Contact us

[email protected]

Follow us

Instagram
Telegram
LinkedIn

All rights reserved.

Privacy Policy Terms of Conditions

Home
Markets
Screener
News
About

BDTX - Black Diamond Therapeutics, Inc.... | Finranks

Home

BDTX

B

Black Diamond Therapeutics, Inc. (BDTX)

NMS – Real Time Price. Currency in USD

2.03

-0.10 (-4.69%)

At close: Mar 27, 2026, 4:00 PM EDT

2.07

+0.04 (1.78%)

After-hours: Mar 27, 2026, 7:55 PM EDT

Summary
News
Chart
Financial
Dividends
Forecast
Ownership
Profile

Black Diamond Therapeutics: Market Is Yawning About These Data, But I See Opportunity

Black Diamond Therapeutics: Market Is Yawning About These Data, But I See Opportunity

Black Diamond Therapeutics (BDTX) remains a 'Buy', as silevertinib shows promising efficacy in EGFR-mutant NSCLC with notable CNS activity. BDTX reported a 60% objective response rate and 86% CNS response rate in phase 2 silevertinib data, addressing key resistance mutations. Cash position supports operations into 2028, allowing BDTX to reach pivotal clinical catalysts before requiring additional funding.

Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

CAMBRIDGE, Mass., March 16, 2026 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, today reported financial results for the fourth quarter and full year ended December 31, 2025, and provided a corporate update.

Black Diamond Therapeutics to Participate in Upcoming Investor Conferences

Black Diamond Therapeutics to Participate in Upcoming Investor Conferences

CAMBRIDGE, Mass., March 02, 2026 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, today announced its participation in upcoming investor conferences. Presentation details with President and Chief Executive Officer, Mark Velleca, M.D., Ph.D. and Chief Scientific Officer Elizabeth Buck, Ph.D., are as follows:

Is Black Diamond Therapeutics (BDTX) Stock Outpacing Its Medical Peers This Year?

Is Black Diamond Therapeutics (BDTX) Stock Outpacing Its Medical Peers This Year?

Here is how Black Diamond (BDTX) and Bionano Genomics, Inc. (BNGO) have performed compared to their sector so far this year.

What Makes Black Diamond (BDTX) a New Strong Buy Stock

What Makes Black Diamond (BDTX) a New Strong Buy Stock

Black Diamond (BDTX) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

New Strong Buy Stocks for January 9th

New Strong Buy Stocks for January 9th

BDTX, LUMN, ADEA, ACRE and TACT have been added to the Zacks Rank #1 (Strong Buy) List on January 9th, 2026.

Down 30.5% in 4 Weeks, Here's Why You Should You Buy the Dip in Black Diamond (BDTX)

Down 30.5% in 4 Weeks, Here's Why You Should You Buy the Dip in Black Diamond (BDTX)

Black Diamond (BDTX) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Videos

No Data

There is no data to display

Press releases

Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

CAMBRIDGE, Mass., March 16, 2026 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, today reported financial results for the fourth quarter and full year ended December 31, 2025, and provided a corporate update.

Black Diamond Therapeutics Announces Preliminary Phase 2 Data for Silevertinib in 1L NSCLC and Plans for a Phase 2 Trial of Silevertinib in GBM

Black Diamond Therapeutics Announces Preliminary Phase 2 Data for Silevertinib in 1L NSCLC and Plans for a Phase 2 Trial of Silevertinib in GBM

CAMBRIDGE, Mass., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, today announced topline data from its Phase 2 trial of silevertinib in frontline (1L) non-small cell lung cancer (NSCLC) patients with non-classical epidermal growth factor receptor (EGFR) mutations (NCMs) and outlined plans for a randomized Phase 2 trial of silevertinib in patients with newly diagnosed glioblastoma (ND GBM).

Black Diamond Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Black Diamond Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

CAMBRIDGE, Mass., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, today reported financial results for the third quarter ended September 30, 2025, and provided a corporate update.

Black Diamond Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Black Diamond Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

CAMBRIDGE, Mass., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, today reported financial results for the second quarter ended June 30, 2025, and provided a corporate update.